There is a reason compounding pharmacies add ingredients to drugs that are commercially available: adding something is the usual justification for compounding at all.
WellMedr offers two combination products. Energy & Focus+ pairs compounded tirzepatide with NAD+ and vitamin B12, marketed for balanced focus, sustained energy and metabolic performance alongside appetite suppression. LipoForce+ pairs tirzepatide with vitamin B12, methionine and inositol — the MIC cofactors — marketed for liver function, fat mobilisation and metabolic efficiency.
Both are described as once-weekly subcutaneous injections with personalised titration set by a board-certified provider. The company states clinical results are generally consistent with standard tirzepatide injections, with patients reporting improved adherence and fewer energy-related side effects.
What its own disclaimer says
“These formulations are intended to support general wellness. Microdosed GLP-1/GIP compounds have not been studied for specific health outcomes. These products are not intended to diagnose, treat, cure, or prevent any disease.”
— WellMedr's published disclaimer, on the same page as the product claims
Those two positions cannot both hold in the way the page presents them. A product marketed as supporting liver function and fat mobilisation is being sold on specific health outcomes; a disclaimer saying it has not been studied for specific health outcomes concedes the evidence does not exist.
The evidence on the added ingredients
We cover NAD+ in detail in our NAD+ guide: the biochemistry is real, the consumer product claims are not established, and Cleveland Clinic's assessment is that the research is not there. B12 is genuinely useful if you are deficient and does nothing measurable if you are not. Methionine and inositol in fat loss rest on decades-old practice rather than trial evidence.
Standard compounded tirzepatide, by contrast, is at least a copy of a molecule with large randomised trials behind it. Adding three unstudied substances to it does not improve that position.
What WellMedr does well
Its description of the clinical process is more thorough than most: detailed intake, provider review with dosing strategy explained before medication starts, ongoing monitoring with adjustments for tolerance, and continued access to the care team. It states that careful screening is deliberate and that not every patient is appropriate for these formulations. It takes no insurance and prescriptions come from an accredited US pharmacy in plain packaging.
None of which changes the two facts that matter: no price is published for anything, and the differentiator is unevidenced by the company's own admission.
What it actually costs per year
Advertised prices in this category are usually medication only. Add the membership back in and the ranking changes. Pick a provider, or enter the quote you were given.
One-month semaglutide rate. Starting at $79/month equivalent requires a 12-month plan ($948 total); confirm payment and renewal terms.
- First month
- $139
- Every month after
- $139
- Total over 12 months
- $1,668
No membership on this plan, so every dollar goes to medication and care.
Figures are the providers' own published prices as of our last review of each. Promotional rates, multi-month prepayment and dose changes can all move these numbers — confirm at checkout.
What compounded tirzepatide actually is
Tirzepatide is the active ingredient in Mounjaro and Zepbound, both FDA-approved products from Eli Lilly. Unlike semaglutide, it acts on two receptors — GLP-1 and GIP — which is the basis for the larger average weight reductions seen in its trials. A compounded version is prepared by a pharmacy and is not FDA-approved or FDA-evaluated.
Compounded tirzepatide is consistently more expensive than compounded semaglutide, typically by $50 to $100 a month. That gap is real and reflects the raw material, so a provider pricing them identically is worth a question rather than a celebration.
Dosing usually starts at 2.5 mg weekly and escalates in 2.5 mg steps. As with semaglutide, dose-flat pricing is worth substantially more than a low starting price, because the starting dose is not the dose most people end up on.
Side effects mirror semaglutide's — predominantly gastrointestinal, worst after dose increases — though some patients report tirzepatide is better tolerated at equivalent efficacy. That is an individual matter and not something a telehealth intake form can predict for you.
Before you buy from anyone
- Get the total monthly cost in writing — medication plus any membership, not the headline figure.
- Ask whether the price changes as your dose increases. This is where most of the money is lost.
- Ask which pharmacy compounds it, and whether it is a 503A or 503B facility.
- Confirm what happens if you stop after one month, and whether there is an auto-rebill.
- Ask whether a refund is available if a provider declines to prescribe.
- Tell the prescriber every medication and supplement you take, including anything bought online.